Lu-177–treated NET patients: new drug versus standard care
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 3 trial tests RYZ101 versus standard of care in people with inoperable, well-differentiated SSTR-positive GI or pancreas neuroendocrine tumors (NETs) that keep growing after Lu-177 SSA. It may help by improving tumor control after your prior targeted radiation treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a biopsy-proven, well-differentiated GI or pancreas NET that cannot be removed by surgery.
- Your tumor is “SSTR-positive” on a scan (SSTR-PET shows high uptake with a Krenning score of 3 or 4).
- Your NET is getting worse after 2–4 cycles of Lu-177 SSA, and you had disease control for at least 6 months after that treatment.
- You have at least one tumor spot that can be measured on imaging, and any spots that look SSTR-negative are not the measurable ones.
- Your kidneys and blood counts are strong enough (kidney filtering test is at least 60; hemoglobin, white blood cells, and platelets meet required cutoffs; liver blood tests are within limits).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called RYZ401 for people with advanced neuroendocrine tumors (NETs) that show a certain marker on scans. The drug is designed to target the tumor cells directly and may be a new option for those who have not had a similar type of targeted radiation therapy.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests a personalized way to give a radioactive drug called Lutathera to people with neuroendocrine tumors (NETs). The goal is to see if adjusting the dose based on how your body absorbs it can be more effective.
This study tests whether combining Lu-177 dotatate (a targeted radiation treatment) with olaparib (a targeted pill) can shrink or slow growth of inoperable gastroenteropancreatic neuroendocrine tumors. It’s designed for tumors that show the right “targets” on a special scan and that have started to progress despite standard care.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
This trial tests whether a radioactive drug called Lu177-Dotatate (PRRT) works better than usual care for people with slow-growing, advanced midgut neuroendocrine tumors (NETs). It may help shrink or slow the growth of tumors when you also get somatostatin analog therapy.
Hear when a new GEP-NET trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.